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Targeting CXCR4 in AML and ALL
Daniel Cancilla, Michael P. Rettig and John F. DiPersio*
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States

The interaction of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)
blasts with the bone marrow microenvironment regulates self-renewal, growth signaling,
as well as chemotherapy resistance. The chemokine receptor, CXC receptor 4 (CXCR4),
with its ligand chemokine ligand 12 (CXCL12), plays a key role in the survival and
migration of normal and malignant stem cells to the bone marrow. High expression of
CXCR4 on AML and ALL blasts has been shown to be a predictor of poor prognosis
for these diseases. Several small molecule inhibitors, short peptides, antibodies, and
antibody drug conjugates have been developed for the purposes of more effective
targeting and killing of malignant cells expressing CXCR4. In this review we will discuss
recent results and strategies in targeting CXCR4 with these agents in patients with AML
or ALL.
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INTRODUCTION
The chemokine receptor 4 (CXCR4) is a member of the G protein coupled receptor (GPCR)
family of receptors and plays a role in numerous biological processes including fetal organ
development, hematopoiesis, and immune system function. It is expressed on a wide range of
hematopoietic cells including hematopoietic stem and progenitor cells (HSPCs) T cells, B cells,
monocytes, macrophages, eosinophils, and neutrophils (1). The CXCR4 receptor was initially
discovered in 1996 and studied in the context of human immunodeficiency virus-1 (HIV-1) as
a co-receptor for viral entry into the cell (2). Further research revealed the role of CXCR4 in
chemotaxis of white blood cells, retention of HSCs in the bone marrow, as well as involvement in
several signaling pathways important for cellular proliferation, survival, and chemotactic migration
[Figure 1A; for review see (3, 4)]. The CXCR4 receptor interacts with the peptide signaling
molecule stromal cell-derived factor 1 (SDF-1), also known as CXCL12, which is produced by bone
marrow endothelial and stromal cells, including CXCL12-abundant reticular (CAR) cells (5–7). The
migration of CXCR4 expressing cells along the CXCL12 gradient contributes to the chemotaxis
of these cells and their retention within the bone marrow niche (7). The pro-survival effects of
the CXCR4-CXCL12 interaction are thought to be mediated by activating mammalian target of
rapamycin (mTOR) and downstream translation, while increased cellular proliferation is induced
via activation of the signaling molecule extracellular signal related kinase (ERK-1/2) (3, 4).
CXCR4 is highly expressed in over 20 cancer types, ranging from hematological malignancies
to solid tumors (8, 9). In leukemia, the receptor contributes to the retention of malignant cells in
the bone marrow, which is thought to offer a protective environment to these cells in the presence
of chemotherapeutic agents. This has been shown across multiple cancer types including acute
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (10, 11). Therefore, CXCR4
might be an attractive molecular target for treating these malignancies. One predominant rationale
for targeting the CXCL12/CXCR4 axis in AML and ALL is that its disruption will not only inhibit
pro-survival signaling but also mobilize the leukemic cells from the protective bone marrow
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FIGURE 1 | Targeting CXCR4. (A) Overview of CXCL12/CXCR4 signal transduction pathways. CXCR4 is a seven-transmembrane spanning G-protein coupled
receptor. Upon binding CXCL12, CXCR4 G-protein-mediated signaling leads to (a) activation of JAK/STAT signaling promoting stemness and survival, (b) activation of
the phosphatidylinositol-3-kinase (PI3K)-Akt-mTOR pathway promoting cell survival and proliferation, (c) activation of Ras/Raf and mitogen-activated protein kinase
(MAPK) signaling leading to phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 which promotes survival and proliferation, (d) activation of
phospholipase C (PLC) leading to diacylglycerol (DAG) and inositol triphosphate (IP3) production which induces Ca2+ efflux and protein kinase C (PKC) activation
resulting in chemotaxis and migration, and (e) inhibition of adenylyl cyclase (AC), which reduces cAMP production and protein kinase A activation leading to reduced
cell proliferation and chemotaxis. CXCL12 also induces CXCR4 desensitization via uncoupling the receptor from G-proteins by GRK-dependent phosphorylation and
subsequent β-arrestin-dependent endocytosis and lysosomal degradation. (B) Inhibitors of the CXCR4/CXCL12 axis. Drugs targeting CXCR4 can be divided into
three general categories: (1) small molecules; (2) peptide-like molecules; and (3) antibodies. NOX-A12 disrupts the CXCR4/CXCL12 axis by binding and neutralizing
CXCL12. (C) Schematic of CXCR4 inhibitor-mediated chemosensitization in leukemia. Osteoblasts, mesenchymal stem/stromal cells (MSC) and CXCL12-abundant
reticular (CAR) cells in the bone marrow niche constitutively express CXCR12 leading to the recruitment and adhesion of CXCR4-expressing leukemia cells. These
interactions provide a protective environment to the malignant cells in the presence of chemotherapeutic agents. Disruption of CXCR4-mediated adhesion of leukemia
cells to the chemoprotective cells in the bone marrow niche via administration of CXCR4 inhibitors promotes mobilization and chemosensitization of leukemia cells.
(D) Alternative approaches to target CXCR4-expressing cells. Antibodies to CXCR4 have been linked to cytotoxic drugs (antibody-drug conjugates; ADC) which
induce cell death via DNA damage and/or microtubule disruption upon internalization. Several small molecule inhibitors and peptide-based antagonists of CXCR4
have been radiolabeled for positron emission tomography (PET) imaging or endoradiotherapy. Nanomaterials are small particles that serve as carriers for
small-molecule drugs, proteins, and nucleic acids. Several nanomaterials targeting CXCR4 with the small molecule inhibitors, antibodies, or peptide-based
antagonists discussed above have been developed.
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adults 60 years or older the 5 year survival rate is <20% (23).
Across all ages, relapse affects over 30% of patients. Relapsed or
refractory ALL is associated with particularly poor outcomes with
a reported 10% 3 year survival rate in B-cell ALL. Outcomes are
even worse in T-cell ALL (24). There is a clear need for additional
therapies that can reduce the rate of relapse in these patients.

environment and out into the vasculature where they might
be more susceptible to conventional chemotherapeutic agents
(Figures 1B,C). This strategy is termed “chemosensitization” and
has been tested in both animal models and human trials.
Recent studies have shown that in addition to being able
to mobilize leukemic cells to the vasculature, some CXCR4
inhibitors have direct cytotoxic effects and can induce apoptosis
in cells expressing the receptor. Because of these properties, there
is growing interest in using CXCR4 inhibitors as part of an
ablative chemotherapy regiment in the setting of hematopoietic
cell transplant (HCT) or even as a monotherapy (12). Several
small molecule inhibitors, short peptides, antibodies, and
antibody drug conjugates (ADC) have been developed for the
purposes of more effective targeting and killing of malignant cells
expressing CXCR4 (13, 14). In this review we will discuss recent
results and strategies in targeting CXCR4 with these agents in
patients with AML or ALL.

CXCR4 EXPRESSION AND AML/ALL
PROGNOSIS
Studies have shown that increased expression of CXCR4 is
associated with poor outcomes in patients with AML and Bcell ALL. This is potentially due to the role CXCR4 plays
in keeping leukemic cells within the bone marrow as well
as its roles in activating pathways that favor the survival,
growth, and chemotherapy resistance of these malignant cells
(1). Leukemic blasts with high CXCR4 expression in cases of
AML was associated with higher rates of relapse and lower
overall survival (25–35). Patients with a FMS-like tyrosine kinase3 internal tandem duplication (FLT3-ITD) or nucleophosmin
mutation express significantly more CXCR4 than their wildtype counterparts (27–29, 31, 32, 36). However, these cytogenetic
abnormalities do not solely account for the elevated CXCR4
expression in the disease as high CXCR4 expression is still a
risk factor for prognosis in normal karyotype patients with AML
(29, 30). Further, CXCR4 in French American British (FAB)
AML-M4 and M5 subtypes is significantly increased relative to
the other FAB and World Health Organization (WHO) AML
subtypes (27–29, 31).
Fewer studies have evaluated CXCR4 expression in ALL. Like
AML, high expression of CXCR4 is associated with worse overall
survival in patients with B-cell ALL (37–41). Although no reports
have linked high CXCR4 expression with a poor prognosis in
T-cell ALL, it has been shown that T cell ALL interaction with
CXCL12 is required for maintenance of disease in mouse models
and that T ALL cells from both humans and mice show higher
CXCR4 expression when compared to healthy cells (42, 43).
There is also evidence that both AML and ALL cells upregulate
CXCR4 during treatment with chemotherapy, suggesting that
CXCR4 may play a role in chemotherapy resistance (44–46).
Taken together, these data suggest that the CXCL12/CXCR4
axis influences outcomes and therapy responsiveness in AML
and ALL.

AML
Acute myeloid leukemia (AML) is a clinically heterogeneous
malignancy. A primary characteristic of this disease is the
elevated level of immature myeloblasts in the marrow or
peripheral blood. It is the leading cause of acute leukemia in the
adult population and accounts for more deaths than any other
leukemia (15). The current prognosis for patients with AML is
poor, with a 5-year survival rate of only 24% (16). Up to 40% of
patients with AML fail to respond to initial therapy and remain
refractory to all available treatment regimens from outset (17). In
general, for relapsed or refractory patients with AML (rrAML),
therapeutic choices are limited and the prognosis is exceptionally
bleak, with a median overall survival of about 4 months (18).
There is no established standard of care for patients with
rrAML (18). Allogeneic hematopoietic cell transplant (HCT) is
regarded as the only strategy with any possibility of a meaningful
period of disease control but is limited by significant transplantrelated morbidity and mortality associated with high doses
of chemotherapy and radiation therapy, which are needed to
prepare patients for transplant, as well as graft-vs.-host disease
(GvHD) (19).

ALL
Acute lymphoblastic leukemia is a hematologic malignancy
characterized by impaired differentiation and proliferation of
lymphoid progenitor cells. The age adjusted incidence of ALL
is ∼1.7 per 100,00 per year, with higher incidence in children
than adults. ALL can be divided into B-cell ALL and T-cell
ALL, with the former making up approximately 75% of cases
and the latter making up ∼25% of cases (20). While treatments
for ALL in children are very effective with cure rates around
90%, treatments in adults are much less effective (21). Despite
improved treatments, including the emergence of bispecific
antibodies, chimeric antigen receptor therapy, and tyrosine
kinase inhibitors for Philadelphia chromosome positive ALL,
the overall adult survival rate is <45% (22). Furthermore, in
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CXCR4 INHIBITION FOR CHEMOTHERAPY
SENSITIZATION
Given the body of evidence demonstrating that CXCR4
is not only a prognostic marker but also plays a role
in leukemia progression, several strategies have emerged to
potentially treat AML and ALL via targeting CXCR4. While
the BM microenvironment supports proper development of
hematopoietic stem and progenitor cells (HSPCs), it can also
serve as a shelter for malignant cells by shielding them from
cytotoxic chemotherapy (Figure 1C). It has been proposed that
there is a sub-population of leukemic cells in AML and ALL
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the original report of CXCR4 serving as a coreceptor for
human immunodeficiency virus (HIV) 1 infection [for review
(76)]. In 2008, the small molecule AMD3100 (plerixafor) was
approved as an HSPC mobilizer (92–94). Clinically, plerixafor,
in combination with granulocyte colony-stimulating factor (GCSF), has proven effective for the mobilization of hematopoietic
stem cells in patients with multiple myeloma (MM) and nonHodgkin’s lymphoma (NHL) undergoing autologous stem cell
transplantation (53). Further, plerixafor has been tested as a
chemosensitizing agent in patients with AML or ALL. Below
we briefly discuss these trials, where patients were treated with
plerixafor alone or in combination with G-CSF in an attempt to
enhance the efficacy of cytotoxic chemotherapy.

know as leukemia initiating stem cells (LSC) that reside within
the protective niche of the bone marrow (47–50). These cells
are thought to be powerful contributors to drug resistance and
relapse in these diseases. Chemosensitization aims to eliminate
this LSC pool of cells by disrupting the interactions that keep
them anchored within the bone marrow and exposing them
to cytotoxic agents (10, 51, 52). In addition to disrupting the
anchorage of the LSC pool within the bone marrow niche, a
secondary effect of targeting CXCR4 is to disrupt the survival
and growth signaling mediated by this receptor. This is evidenced
by studies showing elimination of cancer cells with CXCR4
inhibitor monotherapy (53, 54). Therefore, the combination of
cell detachment and inhibition of pro-survival signaling may
contribute to the efficacy of CXCR4 targeting agents.
Pathways responsible for the anchorage and survival of
malignant cells, and therefore for their therapy resistance,
were found to largely overlap with those described for normal
HSPCs [reviewed in (55–61)]. Numerous studies have shown
that CXCR4 antagonism, defined as the disruption of the
interaction between CXCR4 and CXCL12, leads to mobilization
of HSPCs into the blood circulation. These observations taken
together provide the underlying rational for disruption of the
CXCR4/CXCL12 axis in an attempt to sensitize the malignant
cell populations within the bone marrow. Multiple pre-clinical
studies in mouse models of AML (12, 62–66) or ALL (43,
45, 67–71) have been reviewed elsewhere (10, 42, 51, 72) and
provided proof of principle for the beneficial effects of combining
CXCR4 inhibition with conventional chemotherapy compared to
treatment with chemotherapy alone.
CXCR4 targeting drugs can be divided into four categories:
(1) small molecule CXCR4 antagonists; (2) peptide-like
CXCR4 antagonist; (3) antibodies to CXCR4; and (4) CXCL12
antagonists (Figure 1B). In general, both small molecule and
peptide-like inhibitors of CXCR4 contain cationic regions
capable of binding the predominantly anionic extracellular
region of CXCR4. Crystal structures of CXCR4 complexed
with a small molecule (isotiourea-1t; IT1t), peptide-like
antagonist (CVX15) and a chemokine-like molecule (viral
macrophage inflammatory protein 2) have been reported
(73, 74). Not surprisingly, the peptide-like molecule mimicked
the chemokine-like molecule in binding a major pocket in
CXCR4 that is comprised of transmembrane (TM) domains
three and seven of CXCR4 as well as more buried residues within
the protein. In contrast, the IT1t small molecule bound a minor
pocket between TM1-TM3 and TM7 in CXCR4. Subsequent
site-directed mutational studies with different small molecule
inhibitors have demonstrated that they can bind either the minor
and/or major pockets of CXCR4 [for review see (75, 76)]. Below
we discuss the clinical results published to date with these four
classes of CXCR4 targeting drugs in patients with AML and ALL
(Table 1).

Chemosensitization With Plerixafor Alone
In the initial phase I/II study using a small molecule CXCR4
antagonist as a chemosensitizing agent (NCT00512252), 52
patients with relapsed or refractory AML (rrAML) were
administered plerixafor followed by Mitoxantrone + Etoposide
+ Cytarabine (MEC) chemotherapy for 5 days (77). Like
HSPCs, the mobilization of AML blasts by plerixafor was
transient, and cell counts returned to baseline within 12 h.
Overall, 46% of the patients achieved a complete remission (CR)
or complete remission with incomplete blood count recovery
(CRi), which is a significantly higher rate compared to the
historical response rate of 21% in similar patients receiving
MEC chemotherapy alone (95). However, the median overall
survival was only 8.2 months with a relapse-free survival of
9 months. Of note, the bolus injection of plerixafor in this
trial induced significant upregulation of surface CXCR4 on
AML blasts and increased their CXCL12-mediated chemotaxis.
Since high CXCR4 expression is a marker of poor prognosis in
AML, the plerixafor-mediated upregulation of CXCR4 on AML
blasts might have reduced the efficacy of MEC chemotherapy in
this trial.
In a small phase one trial of pediatric leukemia, 19 patients
with relapsed or refractory leukemia (13 with AML, five with
B-ALL) or myelodysplastic syndrome (MDS; N = 1) were
treated with plerixafor for 5 days followed 4 h later by high
dose cytarabine and etoposide (NCT01319864). This treatment
regimen was well-tolerated although there was only a modest
17% (3/18) clinical response in three patients with AML (78). No
responses were observed in patients with ALL or MDS.
In subsequent trials, the efficacy of plerixafor
chemosensitization was evaluated in newly diagnosed patients
with AML treated with (1) a combination of cytarabine
and daunorubicin (7 + 3 regimen), (2) decitabine, or (3)
clofarabine. In the first trial, 23 patients received cytarabine on
days 1–7, daunorubicin on days 1–3, and plerixafor on days 2–7
(NCT00990054). With this regimen, which was similar in toxicity
to chemotherapy alone, 67% of patients (14/21) demonstrated
complete remission (54). In the second trial (NCT01352650), 69
elderly patients received monthly cycles of a 10 day decitabine
regimen with plerixafor administered 4 h prior to decitabine
during alternating treatment cycles (79). Plerixafor failed to
effectively sensitize the AML blasts to decitabine chemotherapy
with patients exhibiting an overall response rate of 43% that

Chemosensitization With Small Molecule
CXCR4 Antagonist Plerixafor
An extensive array of over 20 different chemical classes of
small molecule CXCR4 antagonists have been developed since
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TABLE 1 | Clinical trials targeting CXCR4 in combination with chemotherapy in AML and ALL.
CXCR4 Inhibitor

Combined regimens

Disease

Phase

Age of enrollment

Plerixafor

Mitoxantrone + Etoposide +
Cytarabine

AML

Plerixafor

Etoposide + Cytarabine

Plerixafor

Daunorubicin + Cytarabine

Plerixafor

Decitabine

AML

Plerixafor

Clofarabine

AML

Plerixafor

G-CSF + Mitoxantrone + Etoposide + AML
Cytarabine

Plerixafor

G-CSF + Daunorubicin + Cytarabine

AML

Plerixafor

G-CSF + Sorafenib

AML

1/2

18+

NCT00943943

(82)

Plerixafor

G-CSF + Fludarabine, Idarubicin, and AML
Cytarabine

1/2

18–65

NCT01435343

(83)

-

G-CSF + Isofamide + Etoposide +
Dexamethasone

B-ALL, T-ALL

1

18+

NCT01331590

(84)

BL-8040

Cytarabine

AML

1

18–75

NCT01838395

(85)

BL-8040

Cytarabine

AML

2

18–75

NCT02502968

-

BL8040

Nelarabine

T-ALL

2

18+

NCT02763384

(86)

LY2510924

Idarubicin + Cytarabine

AML

1

18–70

NCT02652871

(87)

Ulocuplumab

Mitoxantrone + Etoposide +
Cytarabine

AML

1

18+

NCT01120457

(88)

Ulocuplumab

Cytarabine

AML

1

18+

NCT02305563

-

CX-01

Idarubicin + Cytarabine

AML

1

18–80

NCT02056782

(89)

CX-01

Idarubicin + Cytarabine

AML

60+

NCT02873338

(90)

CX-01

Azacitidine

AML

1

18+

NCT02995655

(91)

1/2

18–70

AML, B-ALL, MDS

1

3–29 (Pediatric)

NCT01319864

(78)

AML

1

18–70

NCT00990054

(54)

1

60+

NCT01352650

(79)

1/2

60+

NCT01160354

-

1/2

18–70

NCT00906945

(80)

1

18–65

EudraCT number
2011-000474-56

(81)

NCT00512252

References

(77)

2011-000474-56). Encouragingly, eight of nine evaluable patients
(88%) achieved a response (5-CR; 3-CRi) and seven proceeded
to an allogeneic HSCT. This increased response rate compared
to the first combination trial might have been due to the
enrollment of younger patients with a more favorable risk
stratification (majority of patients were favorable or intermediate
risk). In the third study, sorafenib (days 1–28) was tested in
combination with G-CSF and plerixafor (every other day from
days 1–13) in 33 patients with rrAML with FLT3-ITD mutations
(NCT00943943). A complete response rate of 28% was observed
in 21 evaluable patients, including three patients refractory to
previous FLT3 inhibitors (82). Finally, 57 patients with rrAML
were administered both G-CSF and plerixafor in combination
with fludarabine, idarubicin, and cytarabine (NCT01435343).
Here, fludarabine, cytarabine, G-CSF, and plerixafor were all
administered on days 1–4, while idarubicin was only given on
days 1–3 (83). The overall response rate of 49% (median overall
and disease free survival of 9.9 and 13 months, respectively)
was similar to a historical control group treated without
plerixafor (100).
In contrast to AML, no reports to date describe ALL patients
treated with plerixafor and G-CSF as part of a chemosensitization
trial. However, 13 patients with rrALL (11 B-ALL; 2 T-ALL) were
treated with G-CSF in combination with a salvage chemotherapy
regimen consisting of isofamide with mesna, etoposide, and
dexamethasone (NCT01331590). Three patients (2 B-ALL; 1

was similar to the 47% CR rate achieved in historical controls
receiving decitabine alone (96). In the third trial (NCT01160354),
plerixafor was administered to elderly patients (N = 22) 4–6 h
prior to clofarabine for 5 consecutive days and no outcome data
has been published to date.

Chemosensitization With Plerixafor Plus G-CSF
Since G-CSF acts synergistically when combined with plerixafor
for HSPC mobilization (97, 98), it was proposed that this
combination would more effectively disrupt AML blasts from the
bone marrow microenvironment and render them susceptible
to MEC chemotherapy. This hypothesis was further supported
by previous studies indicating that “priming” with G-CSF prior
to chemotherapy resulted in superior outcomes for patients
receiving induction chemotherapy for AML (99). In the first
chemosensitization trial with plerixafor, 20 patients with rrAML
were treated with G-CSF (days 1–8), plerixafor (days 3–8) and
MEC chemotherapy (days 4–8) (80). This study was terminated
after an interim analysis revealed that only 30% (6 out of
20) of patients achieved a response with a median overall
survival of 7.6 months (NCT00906945). In the second study,
Heiblig et al. (81) tested a G-CSF (days 1–10) plus plerixafor
(days 1–3 and 8–10) mobilization regimen in combination with
daunorubicin (days 1–3), and cytarabine (days 1–3 and 8–
10) in ten patients with AML after their first relapse from
standard (7 + 3) induction chemotherapy (EudraCT number
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antibody-dependent cell-mediated toxicity (ADCC), antibodydependent cellular phagocytosis (ADCP), and/or complementdependent cytotoxicity.
Ulocuplumab, an IgG4 mAb that inhibits the binding of
CXCL12 to CXCR4 and induces caspase-independent apoptosis
on multiple cell lines and primary samples from patients
with AML, chronic lymphocytic leukemia (CLL), and multiple
myeloma (108–110). A phase one trial in 73 adults with
rrAML tested the antibody alone and in combination with
MEC chemotherapy (NCT01120457). A 51% overall CR/CRi
rate was observed in the 43 patients who received ulocuplumab
in combination with MEC chemotherapy (88). Four patients
achieved a CR/CRi upon treatment with BMS-936564 alone
indicating the antibody has some single-agent anti-leukemia
activity (88). A phase 1/2 study testing the antibody in
combination with low dose cytarabine in newly diagnosed
patients with AML was completed in June 2019 (NCT02305563)
but no data has been published to date.

T-ALL) achieved a complete remission (CR/CRi) for an overall
response rate of 23% (84).

Chemosensitization With Peptide-Based
CXCR4 Antagonists
BL-8040 is a 14 residue synthetic peptide that has a high affinity
(1 nM) and a slow dissociation rate (>24 h) from CXCR4 (101).
Abraham et al. (102) demonstrated that BL-8040 directly caused
AML cells to undergo apoptosis both in vitro and in vivo using
various mouse models. In contrast, plerixafor alone did not
elicit the same type of cytotoxic effects as BL-8040 (103). In a
recently completed phase 2a trial (NCT01838395), 42 patients
with rrAML were treated with BL-8040 monotherapy for 2 days
followed by combined administration of BL-8040 and high dose
cytarabine (HiDAC) for 5 days over one to two cycles (85).
The response rate for all dosing levels was 29% (12/42) with
a median overall survival of 9.1 months that was >6.1 month
median survival observed for a historical control group treated
with HiDAC alone (104). In a separate trial (NCT02502968),
patients with AML in first CR are treated with BL-8040 or placebo
and HiDAC as part of a consolidation therapy approach. No data
has been reported to date for this trial. Finally, in an ongoing trial
involving patients with rrT-ALL, BL-8040 is being administered
in combination with nelarabine (NCT02763384). Five of nine
patients enrolled in the study have achieved a complete remission
for an overall response rate of 56% (86).
LY2510924 is a small cyclic peptide containing non-natural
amino acids that potently inhibits the binding of CXCL12
to CXCR4 (IC50 = 0.08 nM) and exhibits a long half-life
(9.16 h) in humans (105). In a recently completed phase I
study (NCT02652871), 11 patients with rrAML were treated
with LY2510924 monotherapy for 7 days followed by combined
administration of LY2510924 with idarubicin and cytarabine for
3 or 4 days (87). The overall response rate of 36% (4/11) was
similar to a historical control group treated with idarubicin and
cytarabine alone (106). One interesting observation from this
trial was that, unlike plerixafor (77), LY2510924 administration
was not associated with an upregulation of surface CXCR4
expression on the AML blasts (87). This lack of CXCR4
upregulation should prevent rapid re-homing of AML blasts
to the protective BM microenvironment and promote the proapoptotic properties of CXCR4 blockade.

Chemosensitization With Inhibitors of
CXCL12
CXCL12 antagonists have been designed for the purposes of
disrupting the CXCR4/CXCL12 axis and sensitizing malignant
cells to chemotherapy. CX-01 (dociparstat sodium; DSTAT)
is a low molecular weight derivative of heparin that binds
CXCL12 and is able to neutralize PF4, an inhibitor of
megakaryopoiesis (111–113). In a small trial of 12 patients
with AML (NCT02056782), CX-01 (days 1–7) was administered
alongside cytarabine (days 1–7) and idarubicin (days 1–3) as part
of induction and consolidation chemotherapy. The treatment
regimen was safe and well-tolerated, with no CX-01-associated
serious events (89). An overall response rate of 92% (11/12) was
attained with all of the responders presenting with de novo AML.
The 92% CR rate is higher than a 71% CR rate observed in a
historical control cohort treated with cytarabine and idarubicin
(114). A follow-up randomized, dose-response phase two study
(NCT02873338) of the same regimen in 66 older patients (>59
years old) with AML recently reported a similar CR rate of 89%
as well as significantly improved event free survival (P = 0.019)
when compared to standard treatment alone (90). In a separate
trial, hypomethylating agent (HMA)-refractory (received four or
more cycles of HMA without response or disease progression on
HMA therapy) patients with AML or MDS were treated with a
7 day continuous infusion of CX-01 and azacitidine in 28 day
cycles (NCT02995655). The median overall response rate in 15
evaluable patients was 27% (4/15) with a median overall survival
of 221 days (91). A randomized Phase three trial evaluating CX01 in combination with standard induction chemotherapy in
newly diagnosed patients with AML is planned.
NOX-A12 is a pegylated L-enantiomeric RNA
oligoribonucleotide (Spiegelmer) that binds and neutralizes
CXCL12 thereby blocking its interaction with CXCR4 and
CXCR7 (115, 116). In a phase one trial with healthy volunteers
(NCT01194934), NOX-A12 was well-tolerated and mobilized
CD34+ HSPCs in dose-dependent manner (116). Peak HSPC
mobilization occurred within 1–4 h of NOX-A12 administration

Chemosensitization With Antibodies to
CXCR4
At least four monoclonal antibodies (mAbs) against CXCR4
(Ulocuplumab, LY2624587, PF-06747143, and hz515H7) have
been tested in humans and many more antibodies, nanobodies,
and other fragments targeting the CXCR4/CXCL12 axis are
in pre-clinical development [for review see Bobkov et al.
(107)]. Compared to small molecule inhibitors and peptidebased antagonists, mAbs exhibit longer blood half-lives (up
to several weeks for IgG) and, depending on the IgG
subclass, can possess Fc domain-mediated effector functions
that facilitate the elimination of target-expressing cells via
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a myeloablative conditioning regimen for HCT in pediatric
and adult patients with AML (Table 2). To our knowledge
no patients with ALL have been treated with this approach
to date.
In the first trial, plerixafor and G-CSF were included as part
of a busulfan and fludarabine conditioning regimen for 45 adult
patients (34 AML, seven MDS, and four CML) undergoing
allogeneic HSCT (NCT00822770) (119). Although there was
no observed difference in overall survival when compared
to historical datasets of patients receiving only busulfan +
fludarabine treatment, patients who received the mobilizing
drugs showed increased rates of myeloid chimerism and lower
rates of graft vs. host disease (GvHD) (119). In follow-up
correlative studies, a negative correlation between survival and
the percentage of AML blasts before and after conditioning
was reported (122). The second trial included 12 adults with
AML in first remission who underwent allogeneic HCT after
receiving conditioning with plerixafor, busulfan, fludarabine, and
400 cGy total body irradiation (NCT01141543) (120). Plerixafor
was administered 6 h before fludarabine and busulfan for up
to 4 consecutive days (days−5 to −2 pre-HCT). Of the 12
patients enrolled, only two experienced disease relapse posttransplantation and six were alive at a median follow-up of
67 months (120). In the third trial, plerixafor was included as
part of a myeloablative conditioning regimen for 12 pediatric
patients with rrAML undergoing a second allogeneic HSCT
(NCT01068301) (121). With a median duration of followup of 332 days, four of the 12 patients (33%) were alive
with two being disease free. Taken together, these studies
demonstrate the safety and feasibility of adding plerixafor to a
myeloablative conditioning regimen for allogeneic HSCT and
further investigation is warranted.

and, in accordance with the plasma-half-life of 38 h, remained
elevated at 4 days after treatment. Although not tested in patients
with AML and ALL to date, encouraging results have been
obtained in clinical trials evaluating NOX-A12 in combination
with bendamustine and rituximab for the treatment of relapsed
or refractory patients with CLL (NCT01486797) (117) or
bortezomib and dexamethasone in relapsed or refractory
patients with multiple myeloma (NCT01521522) (118).

Summary of Chemosensitization Studies
Targeting CXCR4 in Patients With AML
and ALL
The initial clinical trials with plerixafor, BL-8040, Ly2510924, and
ulocuplumab discussed above have demonstrated the feasibility
and safety of combining CXCR4 inhibitors with chemotherapy
in patients with AML or ALL and provided in vivo evidence
for disruption of the CXCR4/CXCL12 signaling axis. However,
results from these studies have been disappointing and, taken
together, there is no obvious benefit over chemotherapy alone.
This is highlighted by the fact that none of the regimens have
entered into randomized phase three trials. The phase 2b study
assessing the safety and efficacy of BL-8040 vs. placebo as part
of a cytarabine-based consolidation chemotherapy regimen in
patients with AML is ongoing (NCT02502968) and the capability
of BL-8040 to directly induce apoptosis in malignant but not
normal cells may enhance the efficacy of chemosensitization.
More favorable clinical responses have been observed following
treatment of de novo AML patients with the CXCL12 antagonist
CX-01 and chemotherapy. A randomized Phase three trial
evaluating CX-01 in combination with standard induction
chemotherapy in newly diagnosed patients with AML is planned.
Since CXCR4 inhibitors haven’t been tested in the upfront
setting, it’s unclear if the enhanced clinical activity observed with
CX-01 is due to its different mechanism of action or the patient
population under study.

USING CXCR4 INHIBITORS TO ENHANCE
DONOR ENGRAFTMENT AFTER HCT

USING CXCR4 INHIBITORS IN
MYELOABLATIVE CHEMOTHERAPY
REGIMENS FOR HCT

Plerixafor has also been tested for its ability to enhance
donor engraftment and hematopoietic recovery after allogeneic
HCT. Following myeloablative conditioning, post-transplant
treatment with plerixafor led to increased recovery of donorderived cells in a murine transplant model (123). However, this
effect was not observed by others following non-myeloablative
conditioning of mice (124). In a phase I/II trial (NCT1280955),
30 patients with high-risk hematologic malignancies (N = 11
patients with ALL; N = 15 patients with AML/MDS) receiving
myeloablative conditioning were treated with plerixafor every
other day beginning day +2 until day +21 or until neutrophil
recovery after allogeneic HCT (125). Plerixafor treatment
had minor effects, with treated patients recovering absolute
platelet counts >20,000/µL only 1 day sooner than untreated
patients. There was no difference in the time to neutrophil
recovery between plerixafor-treated and untreated patients.
This study demonstrated that plerixafor can be administered
safely following myeloablative HCT but has minimal effects on
enhancing hematopoietic recovery when given every other day at
a dose of 240 µg/kg.

All of the clinical studies discussed thus far have combined
disruption of the CXCR4/CXCL12 axis with drug and/or
chemotherapy regimens that were of insufficient intensity
to ablate the recipient’s hematopoietic system. Hematopoietic
stem cell transplantation (HSCT) allows for treatment with
myeloablative therapy without concern for harming normal
HSCs because of the hematopoietic rescue mediated by the
transplanted untreated (i.e., non-chemotherapy-exposed) donor
HSCs. HSCT thus provides a platform to combine CXCR4
antagonism with myeloablative chemotherapy. The rationale for
this approach is that CXCR4 inhibition is thought to enhance
donor HSPC engraftment during myeloablative conditioning by
disrupting recipient HSPC retention within the bone marrow
and sensitizing the recipient’s normal HSPCs and leukemia
stem cells to the cytotoxic conditioning chemotherapy. Below
we discuss three trials where plerixafor was used as part of

Frontiers in Oncology | www.frontiersin.org

7

September 2020 | Volume 10 | Article 1672

Cancilla et al.

CXCR4 in AML/ALL

TABLE 2 | Clinical trials targeting CXCR4 in myeloablative chemotherapy regimens for HCT.
CXCR4 Inhibitor

Combined regimens

Disease

Phase

ClinicalTrials.gov identifier

References

Plerixafor

G-CSF + Busulfan + Fludarabine

Plerixafor

Busulfan + Fludarabine + TBI

AML, MDS, CML

1/2

NCT00822770

(119)

AML

1/2

NCT01141543

Plerixafor

Fludarabine + Thiotepa + Melphalan + rATG

(120)

AML

1

NCT01068301

(121)

TBI, total body irradiation; rATG, rabbit antithymocyte globulin.

TARGETING CXCR4 WITH
ANTIBODY-DRUG CONJUGATES

Pentixather is an analog of pentixafor that allows linkage
of beta emitting radionuclides (177 Lu; 90 Y) that are routinely
used in clinical practice for various cancer radiotherapies
(135, 136). Habringer at al. (137) recently reported that
endoradiotherapy with 177 Lu-pentixather effectively targeted
CXCR4+ tumor cells and significantly reduced leukemic burden
in patient-derived and cell-line-based models of T-ALL and
AML. Subsequent first-in-human studies of CXCR4-directed
endoradiotherapy with 177 Lu-pentixather or 90 Y-pentixather in
22 patients with hematological malignancies (includes four
patients with AML) have demonstrated the feasibility of this
approach when combined with high-dose chemotherapy as
part of a conditioning regimen for autologous or allogeneic
stem cell transplantation (137, 138). Patients became anemic,
neutropenic and thrombocytopenic after treatment with 177 Lupentixather or 90 Y-pentixather (138). This hematological toxicity
was expected as there is a significant “cross-fire” effect from the
radiolabeled pentixather that kills healthy hematopoietic HSPCs
within the bone marrow upon targeting CXCR4-expressing cells.
Although increasing the potential for off-target toxicity, this
cross-fire irradiation may prove beneficial as it eliminates the
need to target every single malignant cell and could disrupt
and/or eradicate the tumor-supporting niche (137). Importantly,
platelet and neutrophil engraftment after HSPC transplantation
were not impaired by the CXCR4-directed endoradiotherapy.
Therefore, the bone marrow niche was capable of supporting
normal HSPCs after 177 Lu-pentixather or 90 Y-pentixather
treatment. Finally, new scaffolds for delivering radiation to
CXCR4 for imaging and endoradiotherapy have recently
been developed from the small molecule CXCR4 inhibitor
LY2510924 (139, 140).

An antibody-drug conjugate (ADC) is a monoclonal antibody
(mAb) conjugated to a cytotoxic drug via a chemical linker
(Figure 1D). Upon binding a target antigen on the surface of
a cell, the ADC complex is internalized and degraded resulting
in the release of the cytotoxic payload and cell death. Two
publications have described ADCs targeting CXCR4 (13, 126).
Costa et al. (126) screened multiple CXCR4-targeted ADCs and
demonstrated efficient killing of multiple AML and ALL cell lines
in vitro and non-small cell lung cancer cells in vivo. Their optimal
ADC, ADC 713, was a low-affinity humanized IgG1 antibody
with reduced Fc-mediator effector function. Tolerability and
safety studies performed in a human CXCR4 knock-in mouse
model (127) revealed significant decreases in the numbers of
circulating neutrophils and monocytes 3 days after the third
injection of ADC 713. Although the numbers of bone marrow
lineage-negative/Sca-positive/Kit-positive (LSK) cells and HSPCs
were unchanged, there was a significant decrease in granulocytemonocyte progenitors, suggesting some hematopoietic toxicity.
Therefore, although CXCR4 may not be an ideal target for
an ADC due to its widespread expression on normal HSPCs,
mature leukocytes, kidney tubular epithelium and the adrenal
gland (128), the majority of these cell populations are largely
quiescent and should be relatively insensitive to auristatinmediated cell killing.

TARGETING CXCR4 WITH RADIONUCLIDE
THERAPY
Several small molecule inhibitors and peptide-based antagonists
of CXCR4 have been radiolabeled for positron emission
tomography (PET) imaging [for review see (129, 130)]. Three of
these compounds: (1) 64 Cu-AMD3100 (131), (2) 68 Ga-NOTANFB (132), and (3) 68 Ga-pentixafor (133) have been tested
in humans. The rapid renal excretion and low non-specific
background accumulation of the high affinity 68 Ga-pentixafor
compound has driven its clinical development as a diagnostic
agent for CXCR4 in hematological and solid cancers as well
as inflammatory conditions (129). A proof-of-concept study
in 10 patients with AML demonstrated variable expression of
CXCR4, with five of ten patients exhibiting 68 Ga-pentixafor
uptake that correlated well with AML infiltration as determined
by magnetic resonance imaging (134). These data suggest that
in vivo imaging of CXCR4 expression in patients with AML is
feasible using 68 Ga-pentixafor.
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TARGETING CXCR4 WITH
NANOMATERIALS
Nanomaterials are small particles that serve as carriers for
small-molecule drugs, proteins, and nucleic acids. Non-targeted
liposomes containing conventional chemotherapeutic agents
exhibit decreased toxicity compared to their corresponding free
drugs and have been approved for use in patients with AML or
ALL. Several pre-clinical studies using nanomaterials targeted
to CXCR4 with the small molecule inhibitors, antibodies, or
peptide-based antagonists discussed above have been reported
[see Wang et al. (141) for review]. Although none of these
pre-clinical studies have tested the efficacy of the CXCR4targeted nanomaterials against ALL cells to date, a couple
of nanomaterial-based approaches have been tested against
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Correlative studies from the chemosensitization trials
discussed above have demonstrated that surface expression
of functional CXCR4 often increases following inhibition of
the CXCR4/CXCL12 axis. This upregulation of CXCR4 on
the leukemic blasts may enhance pro-survival signaling and
re-homing of the leukemic blasts to the protective BM niche
thereby negating the efficacy of cytotoxic chemotherapy. One
potential chemosensitization strategy that warrants further
investigation is combining cytotoxic chemotherapy with a new
class of CXCR4 inhibitors that are capable of biased antagonism
of CXCR4. The peptide X4-2-6, which is derived from the second
transmembrane helix and first extracellular loop of CXCR4, and
small molecule CXCR4 inhibitor SEN071 have been shown in
vitro to selectively inhibit the G protein signaling dependent
chemotaxis mediated via CXCR4 but not the beta arrestin
recruitment and subsequent receptor endocytosis (147–149).
Inhibition of the arrestin mediated endocytosis pathway is a
proposed mechanism of tolerance to CXCR4 antagonists such as
plerixafor (148). Agents such as X4-2-6 and SEN071 that inhibit
G protein signaling of CXCR4 while sparing arrestin function
may have the potential to significantly increase the efficacy of
CXCR4 mediated chemosensitization.
Recently, Ramakrishnan et al. (150) demonstrated that
CXCR4 alone provides sufficient signaling in the absence of
CXCL12 ligation to promote the expansion and survival of
murine AML cells in vivo. Therefore, if CXCR4 expression is
maintained, disruption of the CXCR4/CXL12 axis alone might
be insufficient to effectively sensitize leukemic cells to cytotoxic
chemotherapy. If CXCL12 is indeed dispensable for the growth
and persistence of leukemic blasts (or a subpopulation of LSCs) in
patients with AML and ALL, more effective chemosensitization
might only be attained following concomitant inhibition of
both CXCL12 ligation (via a CXCR4/CXCL12 antagonist) and
CXCR4 signaling. Several inhibitors of the RAS-RAF-MEKERK and PI3K-AKT-mTOR pro-survival signaling pathways
downstream of CXCR4 exist and could be tested [for review
see (151–154)]. Alternatively, inhibition of downstream CXCR4
signaling could be achieved via downregulation of the receptor.
Some previously reported strategies to downregulate CXCR4
include treatment with (i) the small molecule bromodomain and
extra-terminal domain-containing (BET) proteolysis-targeting
chimera (PRTOAC) ARV-825 (155), (ii) lenalidomide or
pomalidomide (156), and (iii) small interfering RNA [for review
see Wang et al. (141)]. Additional pre-clinical studies combining
cytotoxic chemotherapy with inhibition of CXCL12 ligation (via
a CXCR4/CXCL12 inhibitor) and CXCR4 signaling or expression
are warranted.
Finally, novel methods of mobilizing HSPCs continue to
be studied with a number of pre-clinical compounds and/or
regimens under investigation [for review see (157–159)]. Like
healthy HSPCs, AML and ALL blasts express molecules other
than CXCR4 that mediate adherence to BM stromal cells.
Further, these molecules, such as VLA-4, LFA-1, E-selectin,
and CD44, have been shown to provide anti-apoptotic and
anti-proliferative effects and mediate chemotherapy resistance.
Two phase three clinical trials testing the effectiveness of
GMI-1271, an E-selectin inhibitor, to chemosensitize AML
blasts in patients with de novo (NCT03701308) and rrAML

AML. First, Wang et al. (142) used CXCR4-targeted polymeric
nanoparticles containing plerixafor to deliver siRNA against
the transcription factor RUNX1 as well as inhibit the CXCR4CXCL12 axis in a mouse model of AML. Second, Diaz et al.
(143) generated a CXCR4-targeted nanoparticle (via T22 peptide)
containing ricin that was internalized and promoted AML
killing in a CXCR4-dependent manner (143). In general, the
combined capability to block the CXCR4/CXCL12 axis (via
CXCR4 targeting moiety) while simultaneously delivering a drug
payload (via nanomaterial) with a CXCR4-targeted nanomaterial
could potentially enhance the efficacy and safety profile of
therapeutics against AML and ALL. Like CXCR4-targeted
ADCs and endoradiotherapy the main concern with CXCR4targeted nanomaterials is on-target, off-tumor toxicity to normal
cell subsets.

TARGETING CXCR4 IN COMBINATION
WITH IMMUNE CHECKPOINT BLOCKADE
BL-8040 is being tested in combination with the anti-PD-L1
antibody atezolizumab in intermediate and high-risk patients
with AML who have achieved a CR following induction and
consolidation therapy (NCT03154827). The rationale behind
this combination is based on the observation across several
studies that high CXCR4 expression is associated with decreased
immune activation and diminished response to checkpoint
inhibitor treatment (144, 145). The primary endpoint of this
study is to assess whether the combination prolongs relapsefree survival. In addition to AML, the immune-mediated effects
of BL-8040 are being examined in combination with PD-1/PDL1 immune checkpoint inhibitors in several clinical studies
involving solid tumors (pancreatic, gastric, non-small cell lung
cancer). These early-phase studies are being driven by pre-clinical
data demonstrating that CXCR4 antagonism can enhance the
efficacy of immune checkpoint treatment [see Gorbet et al. (146)
for review].

CONCLUSION AND FUTURE
PERSPECTIVE
The CXCR4 receptor plays a crucial role in the maintenance
of leukemia through a variety of mechanisms, including prosurvival signaling and keeping leukemia cells sequestered in
the protective bone marrow niche. This, coupled with its high
level of expression on more than 20 different types of cancers,
including AML and ALL, make it an attractive target for
treatment of these malignancies. To date, the predominant
strategy used to target CXCR4 in patients with AML or ALL
involves disruption of the CXCR4/CXCL12 axis in combination
with cytotoxic chemotherapy.
Since the majority of these studies tested different
chemotherapy regimens and enrolled small numbers
of patients with different baseline characteristics, it’s
difficult to draw definitive conclusions about their relative
effectiveness. In general, the results from these trials have been
disappointing and only CX-01 is progressing toward a phase
three trial.
Frontiers in Oncology | www.frontiersin.org
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